High levels of serum angiogenic growth factors in patients with AL amyloidosis: Comparisons with normal individuals and multiple myeloma patients

British Journal of Haematology

Volumn 150, Issue 5, 2010, Pages 587-591

  Kastritis, Efstathios ^a   Roussou, Maria ^a   Michael, Michalis ^b   Gavriatopoulou, Maria ^a   Michalis, Evridiki ^c   Migkou, Magdalini ^a   Delimpasi, Sossana ^b   Kyrtsonis, Marie Christine ^a   Gogos, Dimitrios ^c   Liapis, Konstantinos ^b   Charitaki, Evangelia ^b   Repousis, Panagiotis ^d   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

Author keywords

amyloidosis; angiogenesis; angiopoietin; myeloma; vascular endothelial growth factor

Indexed keywords

AMYLOID; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BORTEZOMIB; CYTOKINE; LENALIDOMIDE; VASCULOTROPIN; ANGIOGENIC PROTEIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 2; PANCREATIC RIBONUCLEASE; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART DISEASE; HEART INDEX; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANGIOGENIC PROTEINS; ANGIOPOIETIN-1; BIOLOGICAL MARKERS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955817597     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08288.x     Document Type: Article

References (15)

1. Anargyrou, K., Terpos, E., Vassilakopoulos, T.P., Pouli, A., Sachanas, S., Tzenou, T., Masouridis, S., Christoulas, D., Angelopoulou, M.K., Dimitriadou, E.M., Kalpadakis, C., Tsionos, K., Panayiotidis, P., Dimopoulos, M.A., Pangalis, G.A. Kyrtsonis, M.C. (2008) Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica, 93, 451 454.
2. Brenner, D.A., Jain, M., Pimentel, D.R., Wang, B., Connors, L.H., Skinner, M., Apstein, C.S. Liao, R. (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation Research, 94, 1008 1010.
3. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature, 438, 932 936.
4. Chong, A.Y., Caine, G.J., Freestone, B., Blann, A.D. Lip, G.Y. (2004) Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. Journal of the American College of Cardiology, 43, 423 428.
5. Garcia-Garcia, M., Mourad, G., Durfort, M., Garcia-Valero, J. Argiles, A. (2002) Vascular involvement and cell damage in experimental AA and clinical beta(2)-microglobulin amyloidosis. Nephrology, Dialysis, Transplantation, 17, 1450 1456.
6. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. Grateau, G. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319 328.
7. Hoyer, R.J., Leung, N., Witzig, T.E. Lacy, M.Q. (2007) Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. American Journal of Hematology, 82, 409 413.
8. Kastritis, E., Terpos, E., Anagnostopoulos, A., Xilouri, I. Dimopoulos, M.A. (2006) Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. Clinical lymphoma & myeloma, 7, 73 76.
9. Kastritis, E., Katoulis, A., Terpos, E., Panayiotides, I., Gavriatopoulopu, M. Dimopopoulos, M.A. (2008) Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. Clin Lymphoma Myeloma, 8, 359 362.
10. Merlini, G. Stone, M.J. (2006) Dangerous small B-cell clones. Blood, 108, 2520 2530.
11. Modesto, K.M., Dispenzieri, A., Gertz, M., Cauduro, S.A., Khandheria, B.K., Seward, J.B., Kyle, R., Wood, C.M., Bailey, K.R., Tajik, A.J., Miller, F.A., Pellikka, P.A. Abraham, T.P. (2007) Vascular abnormalities in primary amyloidosis. European Heart Journal, 28, 1019 1024.
12. Nakamura, M., Yamabe, H., Osawa, H., Nakamura, N., Shimada, M., Kumasaka, R., Murakami, R., Fujita, T., Osanai, T. Okumura, K. (2006) Hypoxic conditions stimulate the production of angiogenin and vascular endothelial growth factor by human renal proximal tubular epithelial cells in culture. Nephrology, Dialysis, Transplantation, 21, 1489 1495.
13. Podar, K. Anderson, K.C. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 105, 1383 1395.
14. Rajkumar, S.V., Mesa, R.A., Fonseca, R., Schroeder, G., Plevak, M.F., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Gertz, M.A., Kyle, R.A., Russell, S.J. Greipp, P.R. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 8, 2210 2216.
15. Sezer, O., Jakob, C., Eucker, J., Niemoller, K., Gatz, F., Wernecke, K. Possinger, K. (2001) Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology, 66, 83 88.